Literature DB >> 18485900

Autocrine motility factor stimulates the invasiveness of malignant cells as well as up-regulation of matrix metalloproteinase-3 expression via a MAPK pathway.

Arayo Haga1, Tatsuyoshi Funasaka, Yoshihiro Deyashiki, Avraham Raz.   

Abstract

The autocrine motility factor (AMF) is a multifunctional protein that is involved in tumor progression including enhanced invasiveness via induction of matrix metalloproteinase-3 (MMP3). The increase in MMP3 was found in an AMF-high production tumor cell line, and c-Jun, c-Fos and mitogen-activated protein kinases (MAPKs) were also highly phosphorylated compared with the parent line. AMF stimulation induced the rapid phosphorylation of the cellular MAPK cascade and MMP3 secretion, which was blocked using a specific MAPK inhibitor. Results of this study suggest that AMF stimulation stimulates MMP3 expression via a MAPK signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18485900      PMCID: PMC3788612          DOI: 10.1016/j.febslet.2008.05.005

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  48 in total

1.  Tumor autocrine motility factor is an angiogenic factor hat stimulates endothelial cell motility.

Authors:  T Funasaka; A Haga; A Raz; H Nagase
Journal:  Biochem Biophys Res Commun       Date:  2001-06-29       Impact factor: 3.575

2.  Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein.

Authors:  A Haga; Y Niinaka; A Raz
Journal:  Biochim Biophys Acta       Date:  2000-07-14

3.  Neuroleukin inhibition sensitises neuronal cells to caspase-dependent apoptosis.

Authors:  Alessandra Romagnoli; Serafina Oliverio; Cristina Evangelisti; Carlo Iannicola; Giuseppe Ippolito; Mauro Piacentini
Journal:  Biochem Biophys Res Commun       Date:  2003-03-14       Impact factor: 3.575

4.  Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells.

Authors:  Tatsuyoshi Funasaka; Arayo Haga; Avraham Raz; Hisamitsu Nagase
Journal:  Int J Cancer       Date:  2002-09-20       Impact factor: 7.396

5.  Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling.

Authors:  Soichi Tsutsumi; Takashi Yanagawa; Tatsuo Shimura; Tomoharu Fukumori; Victor Hogan; Hiroyuki Kuwano; Avraham Raz
Journal:  J Biol Chem       Date:  2003-06-03       Impact factor: 5.157

6.  Inhibition mechanism of cytokine activity of human autocrine motility factor examined by crystal structure analyses and site-directed mutagenesis studies.

Authors:  Nobutada Tanaka; Arayo Haga; Hiroshi Uemura; Hiroko Akiyama; Tatsuyoshi Funasaka; Hisamitsu Nagase; Avraham Raz; Kazuo T Nakamura
Journal:  J Mol Biol       Date:  2002-05-10       Impact factor: 5.469

7.  Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid.

Authors:  Tatsuyoshi Funasaka; Arayo Haga; Avraham Raz; Hisamitsu Nagase
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

8.  Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts.

Authors:  Soichi Tsutsumi; Victor Hogan; Ivan R Nabi; Avraham Raz
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

9.  Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3.

Authors:  Feng-Ling Yu; Ming-Huei Liao; Jeng-Woei Lee; Wen-Ling Shih
Journal:  Biochem Biophys Res Commun       Date:  2004-01-30       Impact factor: 3.575

10.  Activation of small GTPase Rho is required for autocrine motility factor signaling.

Authors:  Soichi Tsutsumi; Suresh K Gupta; Victor Hogan; John G Collard; Avraham Raz
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  7 in total

1.  Monoclonal antibodies against autocrine motility factor suppress gastric cancer.

Authors:  Hahn-Sun Jung; Su In Lee; Seung-Hoon Kang; Jin Sang Wang; Eun Hee Yang; Byungwook Jeon; Jayhyuk Myung; Ji Young Baek; Song-Kyu Park
Journal:  Oncol Lett       Date:  2017-04-13       Impact factor: 2.967

Review 2.  Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.

Authors:  I A Voutsadakis
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

3.  Up-regulation of Key Glycolysis Proteins in Cancer Development.

Authors:  Nicole Nowak; Anna Kulma; Jan Gutowicz
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

4.  Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma.

Authors:  Juan Bayo; Esteban Fiore; Jorge B Aquino; Mariana Malvicini; Manglio Rizzo; Estanislao Peixoto; Oscar Andriani; Laura Alaniz; Flavia Piccioni; Marcela Bolontrade; Osvaldo Podhajcer; Mariana G Garcia; Guillermo Mazzolini
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

5.  Association between autocrine motility factor receptor gene polymorphism (rs2440472, rs373191257) and glioblastoma multiform in a representative Iranian population.

Authors:  Alireza Eishi Oskouei; Laleh Rafiee; Parvin Mahzouni; Mojgan Gharipour; Shaghayegh Haghjooy Javanmard
Journal:  J Res Med Sci       Date:  2018-11-28       Impact factor: 1.852

6.  Extracellular Neuroleukin Enhances Neuroleukin Secretion From Astrocytes and Promotes Axonal Growth in vitro and in vivo.

Authors:  Yoshitaka Tanie; Norio Tanabe; Tomoharu Kuboyama; Chihiro Tohda
Journal:  Front Pharmacol       Date:  2018-10-30       Impact factor: 5.810

7.  GRP78-Mediated Signaling Contributes to Axonal Growth Resulting in Motor Function Recovery in Spinal Cord-Injured Mice.

Authors:  Yoshitaka Tanie; Tomoharu Kuboyama; Chihiro Tohda
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.